Institution
Candiolo Cancer Institute
Recent research
- BiologyOpen access
Oxaliplatin–fluoropyrimidine combinations are standard adjuvant therapy after radical resection of high-risk stage II and stage III colon cancer but expose many patients to toxicity while failing to prevent relapse in others. PEGASUS was a multicenter, single-arm, phase 2 trial e...
- Health & MedicineOpen access
Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options. The addition of durvalumab or pembrolizumab to cisplatin–gemcitabine improves overall survival (OS), but validated biomarkers of benefit remain limited. Immune-mediated adverse ev...
- BiologyOpen access
The paracrine Ephrin A4/BMP4 feed-forward loop sustains a tumor–CAF vicious cycle in osteosarcoma
Abstract Background Advanced osteosarcoma (OS) remains a clinical challenge due to its aggressive behavior and poor prognosis. Cancer-associated fibroblasts (CAFs) have been shown to contribute to tumor progression, but the tumor–CAF crosstalk in OS is still poorly defined. Eluci...
- Health & Medicine
BACKGROUND AND AIMS: Peritoneal metastases (PMs) represent the most frequent, clinically challenging dissemination pattern in advanced gastric cancer, especially poorly cohesive (PCGC) subtype, and are associated with poor prognosis. We aimed to characterize the transcriptomic la...
- Health & Medicine
Summary Background and Objectives Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC). Patients and Methods We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with...